SCOR IN SYSTEMIC LUPUS ERYTHEMATOSUS

系统性红斑狼疮是一种比较常见的年轻女性疾病。这种疾病会携带 严重的发病率和死亡率。几乎没有，如果有的话，有意义的 自从引进新的药物以来，治疗方面取得了进展。 皮质类固醇。 在这项SCOR应用中，基础科学家和临床研究人员 已经将他们在三所康奈尔大学的专业知识和资源结合起来 纽约市附属医院解决基本缺陷 SLE。这些协作互动将涉及10个实验室和 将利用现有的核心设施。这个研究基地 结合HSS非常大的SLE人群，计算机化的临床 数据库和高质量的临床护理，提供必不可少的 此SCOR应用程序的环境。所有这些的基本主题 这些项目是缺陷/多态，导致 异常导致SLE的表达。在一个案例中，这涉及到 控制耐受性的分子缺陷(项目1)，第二 (项目2)，控制T-B淋巴细胞相互作用的分子，以及 项目3，导致血栓形成或易患某些疾病的分子 患者容易出现血栓并发症。 这项计划的长期目标是应用基本知识 在这些研究中获得，以开发新的治疗方法 治疗系统性红斑狼疮。为此，创建了一个治疗核心，该核心 将鼓励和促进新的治疗策略。

SLE is a relatively common disease of young women. The disease carries a significant morbidity and mortality. Few, if any, significant therapeutic advances have been made since the introduction of corticosteroids. In this SCOR application, basic scientists and clinical investigators have combined their expertise and resources at the three Cornell affiliated Hospitals in New York City to address fundamental defects in SLE. These collaborative interactions will involve 10 laboratories and will utilize already existing Core Facilities. This research base combined with a very large SLE population at HSS, a computerized clinical database and high quality of clinical care, provide the essential environment for this SCOR application. The underlying theme of all of these projects is defects / polymorphisms which are responsible for the abnormalities leading to expression of SLE. In one case this involves defects in molecules controlling tolerance (project 1), in the second (project 2), molecules controlling T-B lymphocyte interaction and, in project 3, molecules that either induce thrombosis or predispose certain patients to develop thrombotic complications. The long term goal of this program is to apply the basic knowledge obtained in these studies to develop new therapeutic approaches to treating SLE. To this end, a Therapeutics Core has been created which will encourage and facilitate new treatment strategies.